

# Journal of Visualized Experiments

## Combined genetic and chemical capsid modifications of adenovirus-based gene transfer vectors for shielding and targeting --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58480R2
Full Title:	Combined genetic and chemical capsid modifications of adenovirus-based gene transfer vectors for shielding and targeting
Keywords:	adenovirus capsid modification shielding targeting gene therapy virotherapy oncolysis
Corresponding Author:	Florian Kreppel University Witten/Herdecke Witten, NRW GERMANY
Corresponding Author's Institution:	University Witten/Herdecke
Corresponding Author E-Mail:	Florian.Kreppel@uni-wh.de
Order of Authors:	Franziska Jönsson Claudia Hagedorn Florian Kreppel
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Chair for Biochemistry and Molecular Medicine, University of Witten/Herdecke, Stockumer Str 10, D-58453 Witten

Faculty of Health  
School of Medicine

Chair of Biochemistry and  
Molecular Medicine

**Florian Kreppel, PhD**  
Full Professor, Chair

Stockumer Strasse 10  
D-58453 Witten, Germany

Phone: +49-2302-926-140  
Fax: +49-2302-926-220  
E-Mail: [florian.kreppel@uni-wh.de](mailto:florian.kreppel@uni-wh.de)  
Home: [www.uni-wh.de](http://www.uni-wh.de)

August 14, 2018

Universität Witten/Herdecke, 58448 Witten

To the  
Editor of  
Journal of Visualized Experiments JoVe

## Revised manuscript submission R2

Dear Editor,

Please find enclosed our revised manuscript entitled “Combined genetic and chemical capsid modifications of adenovirus-based gene transfer vectors for shielding and targeting” that we would like to be considered for publication in Journal of Visualized Experiments. We have carefully addressed your editorial comments and hope that everything is complete now.

Thank you for your consideration of this manuscript. We look forward to hearing from you.

Sincerely yours,



Florian Kreppel

**TITLE:**

Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting

**AUTHORS AND AFFILIATIONS:**

Franziska Jönsson\*, Claudia Hagedorn\*, Florian Kreppel

Center of Biomedical Education and Research, University Witten/Herdecke, Witten, Germany

\*Both authors contributed equally

**Corresponding Author:**

Florian Kreppel

florian.kreppel@uni-wh.de

Tel: +49 2302 926140

**Email Addresses of Co-authors:**

Franziska Jönsson (franziska.joensson@uni-wh.de)

Claudia Hagedorn (claudia.hagedorn@uni-wh.de)

**KEYWORDS:**

Adenovirus, capsid modification, shielding, targeting, gene therapy, virotherapy, oncolysis, geneti-chemical capsid modification

**SUMMARY:**

The protocol described here enables researchers to specifically modify adenovirus capsids at selected sites by simple chemistry. Shielded adenovirus vectors particles and retargeted gene transfer vectors can be generated, and vector host interactions can be studied.

**ABSTRACT:**

Adenovirus vectors are potent tools for genetic vaccination and oncolytic virotherapy. However, they are prone to multiple undesired vector-host interactions, especially after *in vivo* delivery. It is a consensus that the limitations imposed by undesired vector-host interactions can only be overcome if defined modifications of the vector surface are performed. These modifications include shielding of the particles from unwanted interactions and targeting by the introduction of new ligands. The goal of the protocol presented here is to enable the reader to generate shielded and, if desired, retargeted human adenovirus gene transfer vectors or oncolytic viruses. The protocol will enable researchers to modify the surface of adenovirus vector capsids by specific chemical attachment of synthetic polymers, carbohydrates, lipids, or other biological or chemical moieties. It describes the cutting-edge technology of combined genetic and chemical capsid modifications, which have been shown to facilitate the understanding and overcoming of barriers for *in vivo* delivery of adenovirus vectors. A detailed and commented description of the crucial steps for performing specific chemical reactions with biologically active viruses or virus-derived vectors is provided. The technology described in the protocol is based on the genetic introduction of (naturally absent) cysteine residues into solvent-exposed loops of adenovirus-

derived vectors. These cysteine residues provide a specific chemical reactivity that can, after production of the vectors to high titers, be exploited for highly specific and efficient covalent chemical coupling of molecules from a wide variety of substance classes to the vector particles. Importantly, this protocol can easily be adapted to perform a broad variety of different (non-thiol-based) chemical modifications of adenovirus vector capsids. Finally, it is likely that non-enveloped virus-based gene transfer vectors other than adenovirus can be modified from the basis of this protocol.

## INTRODUCTION:

Adenoviruses (Ad), members of the family Adenoviridae, are non-enveloped DNA viruses of which more than 70 types so far have been identified (<http://hadvwg.gmu.edu>). Depending on hemagglutination properties, genome structure, and sequencing results, the 70 Ad types can be divided into seven species (human adenoviruses A to G)<sup>1,2</sup>. The human Ad genome is 38 kb in size and encapsulated by an icosahedral nucleocapsid<sup>3</sup>. Due to their abundance, the capsid protein hexon, penton base, and fiber are all referred to as major capsid proteins. The most abundant and largest capsid protein hexon forms 20 capsid facets, each consisting of 12 hexon homotrimers<sup>4,5</sup>. Penton, located on each icosahedral edge (vertex), consists of pentamers of a penton base and represents the base for the vertex spike that is built of glycosylated fiber trimers<sup>5,6</sup>. The native Ad cell entry is basically composed of two major steps. First, the fiber knob binds to the primary receptor. In Ad types from species A, C, E, and F, this is the coxsackie and adenovirus receptor (CAR). This interaction brings the virion into spatial proximity of the cell surface, thereby facilitating interactions between cellular integrins and RGD-motif in the penton base and consequently inducing cellular responses. Second, changes in the cytoskeleton lead to internalization of the virion and transport to the endosome<sup>7</sup>. Upon partial disassembly in the endosome, the virion is released to the cytoplasm and ultimately travels to the nucleus for replication.

While Ad can be delivered locally (*e.g.*, for genetic vaccination), systemic delivery through the bloodstream as required for onco-virotherapy faces several barriers. While circulating in the bloodstream, injected virions encounter the defense system of the host's immune system, leading to fast neutralization of the virus-based vectors and rendering Ad-based vectors extremely inefficient in systemic applications. Furthermore, the natural hepatotropism of Ad interferes with systemic delivery and must be resolved to redirect Ad to its new target cells.

Germline-encoded natural IgM antibodies of the innate immune system rapidly recognize and bind highly repetitive structures on the surface of the virion<sup>8,9</sup>. These immune complexes then activate the classical and non-classical pathways of the complement system, leading to fast complement-mediated neutralization of a large portion of the virions<sup>8</sup>. A second pathway resulting in major removal of Ad virions is mediated by macrophages<sup>10</sup> and associated with acute toxic and haemodynamic side effects<sup>11,12</sup>. In the case of Ad in particular, Kupffer cells residing in the liver bind to and phagocytically take up the Ad virions *via* specific scavenger receptors, thereby eliminating them from the blood<sup>13-15</sup>. Specific scavenger receptors have also been identified on liver sinusoidal endothelial cells (LSE cells)<sup>16</sup>, and LSE cells also seem to contribute to vector elimination<sup>17</sup>, but to what extent still needs clarification. Furthermore, some Ad types

and its derived vectors are efficiently sequestered by human erythrocytes<sup>18</sup> to which they bind *via* CAR or the complement receptor CR1<sup>19</sup>. Of note, this sequestering mechanism cannot be studied in the mouse model system, in contrast to human erythrocytes, as mouse erythrocytes do not express CAR.

Specific anti-Ad antibodies generated by the adaptive immune system after exposure to Ad either due to previous infections with Ad or after the first delivery in systemic applications raise a further barrier to effective use of Ad vectors, and they should be evaded in efficient systemic delivery.

Finally, the strong hepatotropism of some Ad types (including Ad5) severely hinders application of Ad in systemic therapy. This tropism resulting in hepatocyte transduction is due to the high affinity of the Ad virion to blood coagulation factor X (FX), mediated by the interaction of FX with the Ad hexon protein<sup>20-22</sup>. FX bridges the virion to heparin sulfate glycans (HSPGs) on the surface of hepatocytes<sup>20,23-25</sup>. A crucial factor for this interaction seems to be the specific extent of N- and O-sulfation of the HSPGs in liver cells<sup>24</sup>, which is distinct from HSPGs on other cell types. In addition to this FX-mediated pathway, recent studies suggest further pathways not yet identified that result in Ad transduction of hepatocytes<sup>26-28</sup>.

Recently, it has been shown that FX is not only involved in hepatocyte transduction of Ad, but also by binding, the virion shields the virus particle against neutralization by the complement system<sup>26</sup>. Reduction of hepatocyte transduction by preventing FX binding, therefore, would create the unwanted side effect of increasing Ad neutralization *via* the innate immune system.

A profound knowledge of the complex interactions between vectors and host organisms is therefore necessary to develop more efficient vectors for systemic applications that circumvent the obstacles imposed by the host's organism.

One strategy that has been originally used for therapeutic proteins has been adapted for Ad vectors to at least partially overcome the above described barriers. Antigenicity and immunogenicity of therapeutic protein compounds could be reduced by coupling to polyethylene glycol (PEG)<sup>29,30</sup>. Hence, the covalent coupling of polymers such as PEG or poly[N-(2-hydroxypropyl)methacrylamid] (pHPMA) to the capsid surface shields the vector from unwanted vector-host interactions. Commonly, polymer coupling targets  $\epsilon$ -amine groups from lysine side residues that are randomly distributed on the capsid surface. Vector particles in solution are, due to the hydrophilic nature of the attached polymers, surrounded by a stable water shell that reduces the risk of immune cell recognition or enzymatic degradation. Moreover, PEGylated Ad vectors were shown to evade neutralization by anti-hexon antibodies *in vitro* and in pre-immunized mice *in vivo*<sup>31</sup>. In contrast to genetic capsid modifications, chemical coupling of polymers is performed after production and purification, allowing not only for the use of conventional producer cells and production of high titer vector stocks, but also for simultaneous modification of thousands of amino acids on the capsid surface. However, amine-directed shielding occurs randomly throughout the whole capsid surface, resulting in high heterogeneities and not allowing for modification of specific capsomers. Furthermore, the large polymer moieties

required for beneficial effects impair virus bioactivity<sup>32</sup>.

To overcome these limitations, Kreppel *et al.*<sup>33</sup> introduced a geneti-chemical concept for vector re- and de-targeting. Cysteines were genetically introduced into the virus capsid at solvent-exposed positions like fiber HI-loop<sup>33</sup>, protein IX<sup>34</sup>, and hexon<sup>35,36</sup>. Although not naturally-occurring, cysteine-bearing Ad vectors can be produced at high titers in normal producer cells. Importantly, insertion of cysteines in certain capsomers and in different positions within a single capsomer allows for highly specific modifications of thiol group-reactive moieties. This geneti-chemical approach has been shown to overcome numerous obstacles in Ad vector design. The combination of amine-based PEGylation for detargeting and thiol-based coupling of transferrin to the fiber knob HI-loop has been proven to successfully retarget modified Ad vectors to CAR-deficient cells<sup>33</sup>. Since hexon is involved in most undesired interactions (neutralizing antibodies, blood coagulation factor FX), thiol-based modification strategies were also applied to hexon. Coupling small PEG moieties to HVR5 of hexon prevented Ad vector particles to transduce SKOV-3 cells in the presence of FX, whereas large PEG moieties increased hepatocyte transduction<sup>14,35</sup>. Ad vector particles carrying mutations in the fiber knob inhibiting CAR binding and in HVR7 inhibiting binding of FX (and bearing inserted cysteines in HVR1 for position-specific PEGylation) were shown to evade antibody- and complement-mediated neutralization, as well as scavenger receptor-mediated uptake without loss of infectivity. Interestingly, despite a lack of the natural FX shield, PEGylation again improved transduction of hepatocytes as a function of PEG size<sup>36</sup>. However, it was shown that covalent shielding does have an impact on intracellular trafficking processes. Prill *et al.* compared irreversible versus bioresponsive shields based on pHPMA and demonstrated that neither the mode of shielding nor co-polymer charge had an impact on cell entry but did affect particle trafficking to the nucleus. Employing a bioresponsive shield with positively charged pHPMA co-polymers allowed for particle trafficking to the nucleus, maintaining the high transduction efficiencies of Ad vectors *in vitro* and *in vivo*<sup>37</sup>.

In summary, these data indicate that, even under the assumption that all vector-host-interactions were known and considered, excessive capsid surface modifications are necessary to overcome the hurdles associated with systemic vector delivery.

Here we provide a protocol to perform site-specific chemical modifications of adenovirus vector capsids for shielding and/or retargeting of adenovirus vector particles and adenovirus-based oncolytic viruses. The concept of this technology is outlined in **Figure 1**. It allows the shielding of certain capsid regions from unwanted interactions by covalent attachment of synthetic polymers. At the same, it also provides a means to attach ligands and combine shielding and targeting. Using simple chemistry, experimenters will be able to covalently modify adenovirus vector surface with a wide variety of molecules including peptides/proteins, carbohydrates, lipids, and other small molecules. Furthermore, the protocol provides a general concept for the chemical modification of biologically active virus-derived vectors under maintenance of their biological integrity and activity.

#### **PROTOCOL:**

Note: In the following, a protocol for geneti-chemical PEGylation of an Ad vector is described to

detail. To enable specific coupling of the PEG moiety, an Ad5 vector was beforehand genetically modified by introducing a cysteine residue into the hexon protein at the hypervariable loop 5 as described in a previous publication<sup>36</sup>, and a maleimide-activated PEG compound is used as coupling compound.

## **1. Preparation of Buffers for Vector Purification by CsCl Step Gradients**

1.1. Prepare 400 mL of Adenovirus buffer (Ad-buffer) by adding 50 mM HEPES (4.76 g/400 mL) and 150 mM NaCl (3.504 g/400 mL) to double-distilled water (ddH<sub>2</sub>O). 350 mL of this buffer is needed to prepare the following three Ad-buffer variants.

1.1.1. Variant A: adjust 150 mL of Ad-buffer to pH 7.6 with NaOH.

1.1.2. Variant B: add a final concentration of 10 mM TCEP [tris(2-carboxyethyl)phosphine], 0.143 g] to 50 mL and adjust it to pH 7.2 with HCl.

1.1.3. Variant C: add a final concentration of 0.5 mM TCEP (0.022 g) to 150 mL and adjust it to pH 7.2 with HCl.

1.1.4. Prepare the buffers in ddH<sub>2</sub>O and analytical grade chemicals. Use 100 mL each of variant A and variant C to prepare the CsCl buffers (see steps 1.2 and 1.3; 50 mL of each) necessary for the CsCl step gradients (see steps 3.2.6. and 3.2.18).

1.2. Preparing the CsCl step gradient buffer ( $\rho_{\text{CsCl}} = 1.41 \text{ g/cm}^3$ ) in Ad-buffer

Note: This buffer will be needed in two different variations:

1.2.1. Weigh two aliquots of exactly 27.42 g of CsCl into 50 mL tubes.

1.2.2.  $\rho_{\text{CsCl}} = 1.41/\text{TCEP}$  buffer: resolve CsCl in 40 mL of variant C of Ad-buffer.

1.2.3.  $\rho_{\text{CsCl}} = 1.41$  buffer: resolve CsCl in 40 mL of variant A of Ad-buffer.

1.2.4. Check, and if necessary, adjust the pH with HCl. Fill up to exactly 50 mL with the corresponding Ad-buffer variant. To achieve the best separation results, the exact CsCl concentration and pH are crucial.

**1.2.5. Check the density (CsCl content) by weighing 1 mL (1.41 g) of each gradient buffer.**

1.3. Preparing the CsCl step gradient buffer ( $\rho_{\text{CsCl}} = 1.27 \text{ g/cm}^3$ ) in Ad-buffer

Note: This buffer is needed in two different variations:

1.3.1. Weigh two aliquots of exactly 18.46 g of CsCl in 50 mL tubes.

1.3.2.  $\rho_{\text{CsCl}} = 1.27/\text{TCEP}$  buffer: resolve CsCl in 40 mL of variant C of Ad-buffer.

1.3.3.  $\rho_{\text{CsCl}} = 1.27$  buffer: resolve CsCl in 40 mL of variant A of Ad-buffer.

1.3.4. Check, and if necessary, adjust the pH with HCl. Finally, fill up to exactly 50 mL with the corresponding Ad-buffer variant. To achieve the best separation results, the exact CsCl concentration and pH are crucial.

1.3.5. Check the density (CsCl content) by weighing 1 mL (1.27 g) of each gradient buffer.

1.4. Sterilize all buffers (Ad-buffers and CsCl step gradient buffers) by filtration (using 0.45  $\mu\text{m}$  mesh pore size) into sterile bottles.

1.5. After sterilization, to prevent oxidation of TCEP, saturate and overlay the buffers containing TCEP with argon by sparging the buffers with argon gas for about 30 s. Take care to only use sterile devices (*e.g.*, sterile pipette tips) when applying the argon gas, and use bottles large enough to allow argon blubber.

Note: All buffers should be prepared fresh and protected from light and can be stored at 4 °C for several days (especially the CsCl step gradient buffers that should only be kept for a few days).

## 2. Coupling Moieties: Storage and Preparation

Note: Moieties used for coupling to cysteines need to bear thiol-reactive groups. Maleimide-activated compounds will form stable thioether bonds with the genetically introduced cysteines. Alternatively, ortho-pyridyldisulfide (OPSS)-activated compounds can be used, which form bioresponsive disulfide bridges between the vector particles and coupling moiety. Lyophilized malPEG-750 as well as most other coupling reagents are sensitive to hydrolysis and should be stored dry in the form of lyophilized powders at -80 °C.

2.1. To prevent the build-up of condensing water upon thawing of the vials, store the vials in larger tubes (*e.g.*, 50 mL tubes) filled with a cushion of silica gel beads. Store these tubes in an adequate larger container also filled with a silica gel bead cushion.

2.2. Before tightly closing each tube and container, exchange air with argon gas. This can be achieved by placing the open tubes and containers into a desiccator, followed by removing and replacing the air with argon gas. Since argon gas is heavier than air, tubes and containers are filled up with argon gas and can now be placed into each other, with each lid tightly closed.

2.3. Store containers at -80 °C.

2.4. When thawing, place the containers onto silica beads in a desiccator and slowly warm them up to room temperature, then open the container.



2.5. When performing a coupling reaction, freshly resolve the amount of coupling substrate needed into the appropriate solvent. Take care not to add more than 10% of coupling solution to the final coupling reaction, especially if DMF or DMSO is used as the solvent for the coupling substrate.

### **3. Amplification, Purification and Chemical Modification of Ad Vectors:**

#### **3.1. Amplification of Ad vectors**

Note: The following steps must be performed using a safety cabinet according to local biological safety rules.

3.1.1. Transfect a replication deficient  $\Delta E1$  Ad vector containing one (or several) genetically introduced cysteine residue(s) into HEK 293 cells as described by Kratzer and Kreppel<sup>38</sup>.

3.1.2. According to the protocol<sup>38</sup>, amplify the vector by sequential reinfections up to a final preparative infection of 15-20 large (15 cm) cell culture plates (approximately  $1-2 \times 10^7$  cells/plate).

Note: Optimally, the last reinfection should be timed so that cells show full cytopathic effect (CPE) on the morning of purification and modification performance (see **Figure 2**).

3.1.3. After the final amplification step, cells resuspended in Ad buffer + 10 mM TCEP (variant B) can be frozen at -80 °C; however, for optimal yield of vector particles, an immediate follow-up of cell lysis and vector purification and modification is recommended.

#### **3.2. Purification and chemical modification of Ad vectors**

Note: Purification of vectors is performed according to the adenovirus purification protocol described in<sup>38</sup> but under non-oxidizing conditions. Cell harvesting and lysis as well as vector purification and chemical modification can be performed within one day. Harvest and lyse the infected cells according to the protocol described previously<sup>38</sup>.

3.2.1. Collect cells by scraping the plates and transferring the supernatant to 200-500 mL centrifugation tubes.

3.2.2. Spin the cell solution for 10 min at 400 x g.

3.2.3. Resuspend the cell pellet in 4 mL of Ad-buffer + 10 mM TCEP (pH 7.2) (variant B) and transfer to a sterile 50 mL tube. If cell yield is low or only a weak CPE was induced, resuspend it in 2 mL.

3.2.4. Rescue the vector by 3 cycles of freezing (in liquid nitrogen) and thawing (in a 37 °C water

bath).

3.2.5. Spin for 10 min at 5,000 x g at 4 °C.

3.2.6. While centrifuging, prepare two equal CsCl step gradients:

3.2.6.1. First, as the lower phase, add 3 mL of 1.41 g/cm<sup>3</sup> pCsCl in Ad-buffer + 0.5 mM TCEP (pH 7.2, variant C) into the ultracentrifuge tubes. Mark the level of the lower phase on the tube before loading the upper phase.

3.2.6.2. Carefully stack the upper phase of 5 mL of 1.27 g/cm<sup>3</sup> pCsCl in Ad-buffer + 0.5 mM TCEP (pH 7.2, variant C) by very slowly pipetting the 5 mL volume along the walls of the tube onto the lower phase.

Note: Since during coupling a high concentration of TCEP could react with the maleimide residue of malPEG-750 and lead to reduced coupling efficiency, purification by CsCl step gradient needs to be already performed under a reduced TCEP concentration.

3.2.7. Load the supernatant onto the CsCl gradient [either equally divide the supernatant onto both gradients or, in the case of a low vector yield (see above), load the supernatant onto only one column], and fill both gradients equally to the top with Ad buffer + 10 mM TCEP (pH 7.2, variant B).

3.2.8. Adjust the weight of the opposite tubes to a 0.0 g weight difference.

3.2.9. Ultracentrifuge for 2 h at 176,000 x g at 4 °C.

3.2.10. With a clamp, fix the ultracentrifugation tube to a stand, leaving the area around the lower phase level mark accessible. Place the gooseneck lamp above the tube. Around the mark, at the border between the lower and upper phases, a distinct band (the vector virions) should be visible (**Figures 3A-3C**).

3.2.11. Collect the vectors by puncturing the tube with a needle and aspirating the vector band into a syringe. Transfer collected vector virions to a 15 mL tube.

Note: Weaker bands above the Ad vector band contain incomplete vector particles and should be avoided for aspiration. The cell debris and green fluorescent protein (EGFP) of EGFP-expressing Ad-vectors will collect in the upper part of the ultracentrifuge tube (see **Figures 3A and 3B**). This and the following steps up to coupling (step 3.2.16) should be performed speedily, as the vectors are now sensible to disulfide bonding due to the low TCEP concentration.

3.2.12. To calculate the amount of coupling substrate needed for efficient complete binding of the substrate to all cysteine residues in the vector preparation, measure OD<sub>260</sub>:

3.2.12.1. According to the protocol described by Kratzer and Kreppel<sup>38</sup>, vortex a mixture of 10 µL of the collected vector virions, 89 µL of Ad buffer, and 1 µL of 10% SDS. As a blank probe, vortex 99 µL of Ad-buffer and 1 µL of 10% SDS.

3.2.12.2. To denature the virions, incubate both at 56 °C for 10 min.

3.2.12.3. Determine OD<sub>260</sub>.

3.2.12.4. Calculate the physical vector titer per µL using the following equation: OD<sub>260</sub> x Factor of dilution x Empirically determined extinction coefficient of Ad ( $1.1 \times 10^9$  vector particles = 1 OD<sub>260</sub> unit/µL). Therefore, a measured OD<sub>260</sub> of 1.36 of a vector diluted 1:10, would calculate to:  $1.36 \times 10 \times 1.1 \times 10^9 =$  approximately  $1.5 \times 10^{10}$  vector particles/µL.

Note: This titer is only a rough estimation; however, it is accurate enough for the stoichiometric calculations outlined in the following.

3.2.13. Depending on the protein modified by introduction of a cysteine, determine the amount of coupling substrate (in grams) for an efficient coupling reaction, according to the following general equation: Virus titer x Volume x Number of cysteines x Excess of moiety x Molecular weight of moiety /  $6,022 \times 10^{23} =$  grams of coupling substrate.

Note: In this equation: 1) virus titer is the titer/µL, determined by OD<sub>260</sub> as described above, 2) volume accounts for the volume in µL of aspired vector used in the coupling reaction, 3) the number of cysteines is the number of proteins into which the cysteine residue was introduced per vector particle, 4) excess of moiety is the factor of moiety excess necessary for an efficient coupling reaction (50x), and 5) the molecular weight of moiety must be introduced as Da (not kDa).

3.2.14. Freshly resolve the amount of compound (or feasible amount) needed in the appropriate solvent.

Note: As the amount of coupling substrate needed is low and difficult to weigh but expensive, weigh the minimal amount of compound possible and dissolve it in an appropriate concentration for application to the coupling reaction.

3.2.15. Transfer the vector solution to an appropriate size tube (e.g., 2 mL tube) and add the calculated amount of coupling compound stock solution to the vector.

3.2.16. Gently mix the solution by overhead rotation for 1 h at room temperature.

3.2.17. Fill up the vector solution to 6 mL total volume with Ad-buffer (pH 7.6, variant A).

Note: This step must be performed before the solution is applied to the step gradient to ensure that the vector solution, which still contains CsCl from the first step gradient, has a density below

1.27 g/mL.

3.2.18. In a second CsCl banding step, purify the vector from the unreacted coupling moiety:

3.2.18.1. Prepare two equal CsCl step gradients by performing the following steps for each: 1) Lower phase: 3 mL of 1.41 g/cm<sup>3</sup> ρCsCl in Ad-buffer (pH 7.6, variant A), 2) mark level of lower phase on the tube before loading upper phase, and 3) upper phase: 5 mL of 1.27 g/cm<sup>3</sup> ρCsCl in Ad-buffer (pH 7.6, variant A).

Note: After coupling has taken place, buffers without TCEP are used, as no free thiol groups should now be present on the vector capsids.

3.2.18.2. Load the supernatant onto the CsCl gradient and fill both gradients equally to the top with Ad-buffer (pH 7.6, variant A).

3.2.18.3. Adjust the weights of the opposite tubes to a 0.0 g weight difference.

3.2.19. Ultracentrifuge for 2 h at 176,000 x g at 4 °C.

3.2.20. Shortly before the end of ultracentrifugation, equilibrate a PD-10 column 5 times with 5 mL of Ad-buffer (pH 7.6, variant A).

3.2.21. As done in step 3.2.10, fix the ultracentrifugation tube to stand leaving area around the lower phase level mark accessible. Place the gooseneck lamp above the tube. Again, around the border between the lower and upper phases, a distinct band (the vector virions) should be visible (**Figure 3C**).

3.2.22. Collect the vectors by puncturing the tube with a needle and aspirating the vector band into a syringe, and transfer the vector to a 15 mL tube. Take care to collect the virions of both gradient tubes together as a 2.5 mL total volume or less. If a smaller volume is collected, fill to obtain a 2.5 mL total volume with Ad buffer (variant A).

3.2.23. Load the 2.5 mL onto the equilibrated PD-column. Discard the flow-through.

3.2.24. Add 3 mL of Ad buffer (variant A) onto the column and collect the flow-through (containing the purified vector virions).

3.2.25. Add glycerol (333 µL) to obtain a final concentration of 10% and divide into suitable aliquots (e.g., 400 µL each), and include an aliquot of 20 µL for titer determination by OD<sub>260</sub> measurement.

3.2.26. Store the vector solution at -80 °C.

3.2.27. Determine the titer of vector by measuring the OD<sub>260</sub> of 20 µL vector solution, 79 µL of

Ad-buffer (variant A), and 1  $\mu$ L of 10% SDS as described in step 3.2.12. As a blank, use 79  $\mu$ L of Ad-buffer (variant A), 10  $\mu$ L of 10% glycerol, and 1  $\mu$ L of 10% SDS.

3.2.28. Calculate the vector titer as:  $OD_{260} \times \text{Factor of dilution} \times 1.1 \times 10^9$  vector particles/ $\mu$ L. As prepared in step 3.2.27, calculate:  $OD_{260} \times 5 \times 1.1 \times 10^9$  vector particles/ $\mu$ L

#### 4. Verification of Coupling by SDS-PAGE:

Note: If compounds with sufficiently high molecular weights are used for coupling to Ad virions, coupling can be verified by polyacrylamide gel electrophoresis (SDS-PAGE). Successful coupling should then result in a shift of the protein band corresponding to the modified Ad virion protein, compared to the protein in the unmodified Ad virion (see **Figure 4**).

4.1. According to the calculated titer of vector (step 3.2.28), separate  $1-2 \times 10^{10}$  vector particles by SDS-PAGE (8%).

4.2. Develop the gel by silver-staining of the gel<sup>39</sup> to detect even weak protein bands:

4.2.1. Prepare buffers for silver staining (the amounts needed for 100 mL of buffer are indicated in brackets):

4.2.1.1. Prepare buffer 1 by mixing 38 mL of ddH<sub>2</sub>O, 50% MeOH (50 mL of 100% MeOH), 12% AcOH (12 mL of 100% AcOH), and 0.0185% HCHO (50  $\mu$ L of 37% HCHO).

4.2.1.2. Prepare buffer 2 by adding 50% EtOH (50 mL of 100% EtOH) to 50 mL of ddH<sub>2</sub>O.

4.2.1.3. Prepare buffer 3 by adding 0.127 g/L Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (12.744 mg) to 100 mL of ddH<sub>2</sub>O.

4.2.1.4. Prepare buffer 4 by adding 2 g/L AgNO<sub>3</sub> (0.2 g) and 0.0185% HCHO (50  $\mu$ L of 37% HCHO) to 100 mL of ddH<sub>2</sub>O.

4.2.1.5. Prepare buffer 5 by adding 60 g/L Na<sub>2</sub>CO<sub>3</sub> (6 g), 0.0185% HCHO (50  $\mu$ L of 37% HCHO), and 2.5 mg/L Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (0.256 mg) to ddH<sub>2</sub>O to obtain a final volume of 100 mL.

4.2.1.6. Prepare buffer 6 by mixing 38 mL of ddH<sub>2</sub>O, 50% MeOH (50 mL of 100% MeOH), and 12% AcOH (12 mL of 100% AcOH).

4.2.1.7. Prepare buffer 7 by mixing 60 mL of ddH<sub>2</sub>O, 30% MeOH (30 mL of 100% MeOH), and 10% glycerine (10 mL of 100% glycerine).

4.2.1.8. Prepare buffer 8 by mixing 10% glycerine (10 mL of 100% glycerine) with 90 mL of ddH<sub>2</sub>O.

4.3. Performing silver staining

- 4.3.1 Fix the gel in buffer 1 for 30 min.
- 4.3.2 Wash the gel in buffer 2 for 15 min.
- 4.3.3 Pretreat the gel in buffer 3 for 1 min.
- 4.3.4 Wash the gel 3 times in ddH<sub>2</sub>O for 20 s.
- 4.3.5 Impregnate the gel in buffer 4 for 20 min.
- 4.3.6 Wash the gel 2 times in ddH<sub>2</sub>O for 20 s.
- 4.3.7 Develop the gel in buffer 5 until bands are visible (10 s to 10 min).
- 4.3.8 Wash the gel 2 times in ddH<sub>2</sub>O for 2 min.
- 4.3.9 Stop development in buffer 6 for 5 min.
- 4.3.10 Conserve the gel in buffer 7 for 20 min.
- 4.3.11 Store the gel in buffer 8.

Note: Coupling efficiency can be determined by densitometric quantification of the modified and unmodified bands of the targeted capsomere.

#### REPRESENTATIVE RESULTS:

**Figure 2** shows examples of the cytopathic effect (CPE) on 293 cells that indicates successful vector production. Cells should show morphology (**Figure 2C**) 40-48 hours after inoculation with the virus vector. The right timepoint for harvesting is crucial for not losing virus particles by cell lysis and preventing oxidation of the genetically introduced thiol groups. If vector particles are released into the medium by cell lysis, the genetically introduced thiols will almost immediately become oxidized, and it will become difficult to purify and chemically modify them.

**Figure 3** shows exemplary CsCl bands. The purpose of discontinuous CsCl banding before chemical modification is to remove cellular debris from the virus particles. The modification itself can then take place in CsCl. The second banding after chemical modification serves to remove an excess of (unreacted) coupling moiety. Of note, a successful modification of the virus cannot be seen in the gradient and requires further molecular analysis, ideally by SDS-PAGE.

**Figure 4** shows typical examples of successful capsid modifications. Most moieties coupled to specific capsomeres will alter the running behavior of respective capsomeres in SDS-PAGE. By direct comparison with an unmodified control, the success of coupling can be verified, and densitometric analysis can help determine overall coupling efficiency (the percent of shifted and unshifted bands for the modified capsomere).

## FIGURE AND TABLE LEGENDS:

**Figure 1: Combined genetic and chemical capsid modifications of adenovirus vector capsids enable covalent attachment of shielding polymers and targeting ligands.** Cysteine residues are genetically introduced at selected, solvent-exposed capsid loops of adenovirus vector capsids to equip the vector particles with new chemical reactivity. The vectors can be produced using conventional producer cells and protocols. After production, the genetically introduced cysteine residues are specifically and covalently modified with thiol-reactive coupling moieties (ligands, shielding polymers, carbohydrates, small molecules, fluorescent dyes, *etc.*). For coupling, maleimide-activated compounds (which form stable thioether bonds with the vector particle surface) or pyridyldisulfide derivatives (which form bioresponsive disulfide bridges) can be employed. After coupling, the vectors are purified by discontinuous CsCl banding to remove unreacted excess coupling moieties. PEG, polyethylene glycol (shielding polymer); L, ligands (derived from a broad variety of substance classes); -SH, thiol functionality of the genetically introduced cysteine residues. Using this technology, a defined number of molecules can be covalently coupled to the vector capsids, and a precise selection of the coupling site is feasible.

**Figure 2: Cytopathic effect during vector production.** Conventional producer cells (here, 293-HEK cells) can be used for production of the genetically modified vectors prior to chemical modification. The appearance of CPE indicates the best timepoint to harvest the cells. (A) Cells two hours after infection, (B) cells 24 hours after infection, and (C) cells 40 hours after infection prior to harvesting. Scale bars = 20  $\mu$ m.

**Figure 3: Exemplary results of CsCl gradients.** CsCl gradients before (A, B) and after (C) chemical modification. (A) An adenovirus vector is banded by discontinuous CsCl density gradient centrifugation. The upper phase appears green since the vector shown bears an hCMV-promoter-driven expression cassette for EGFP. The vector virion is banded as a single, white band in the lower third of the tube. The two smaller bands (above) stem from incomplete particles, which should not be collected. (B) A cysteine-bearing EGFP-expressing Ad vector before chemical modification. (C) The same vector after modification. The band in the lower third of the tube will be collected and purified by a desalting column. The pen mark in B and C labels the border of the two densities and allows for identifying the location of the vector band that will be collected.

**Figure 4: Silver-stained SDS-PAGE to assess coupling efficiency.** MW marker in lane 1. A vector with cysteines introduced into the capsomeres penton base, and hexon was left unmodified (lane 2) or modified with maleimide-activated PEG (polyethylene glycol) with a molecular weight of 5 kDa (lane 3). Both hexon and penton base exhibit a shift during SDS-PAGE, indicating successful modification of > 90% of the monomers per capsid. A vector with a cysteine residue in hexon was left unmodified (lane 4), modified with 5 kDa PEG (lane 5), or with 20 kDa PEG (lane 6). It should be noted that the larger shift of the hexon band is due to the higher molecular weight of the 20 kDa PEG, compared to the 5 kDa PEG (lane 5). The gel demonstrates specificity and efficiency of the coupling.

## DISCUSSION:

The efficiency by which the genetically introduced cysteines can be chemically modified is typically 80-99%, and certain variables influence this efficiency. First, it is paramount that the genetically introduced cysteines do not undergo premature oxidation. While being well-protected in the reducing environment of the producer cells, it is mandatory to provide a non-oxidative environment after releasing vector particles from the producer cells and during chemical modification. To this end, reducing reagents can be used at concentrations from 0.1-10 mM, and it is necessary to use reducing reagents that do not contain thiol groups, which would readily react with maleimide-activated compounds. Second, when using maleimide-activated compounds, pH during the coupling reaction should not exceed 7.35, since a pH of greater than 7.4 can decrease the specificity of the reaction. Third, in any case, amine-free buffers (*e.g.*, HEPES, PBS) should be used for the reaction. Of note, cysteine-bearing vector particles can be purified by double CsCl banding as described, then stored in HEPES/10% glycerol prior to chemical modification. In this case, 0.1-1 mM TCEP should be used as a reducing reagent, or preferably, the vectors should be stored in an argon atmosphere. Argon-filled plastic jars with lids can be used for this purpose. Additionally, modification efficiency is influenced by the hydrodynamic diameter of the compound coupled to the capsids and the site to which it is coupled. Many capsomeres that can serve as targets for the specific genetic-chemical modification are present in the capsid as trimers (fiber, hexon) or pentamers (penton base). Therefore, depending on the location of the genetically introduced cysteine, a moiety molecule coupled to one monomer might sterically hinder the coupling of another molecule to the neighboring monomer. This should be considered when selecting ideal sites for genetic-chemical capsid modifications.

To facilitate troubleshooting, a few problems may arise when following the protocol described. First, low vector yields (below 10,000 vector particles per producer cell) may result from suboptimal infection of producer cells. Ideally, 100-300 MOI should be used for the infection of producer cells. Please note that both too-high and too-low vector amounts for the inoculum generate suboptimal yields. It is ideal to passage the producer cells the day before infection. Second, smeary bands in the CsCl gradients can appear. The most frequent reason for smeary appearance of bands in the CsCl gradients is a pH of the CsCl solutions that is too acidic. The reducing reagent TCEP is very acidic, and care must be taken to adjust pH before loading the vector onto the gradient, since adenovirus vectors readily disintegrate in an acidic environment. Third, low coupling efficiencies (< 80% of coupling) are the most frequent result of impure vector preparations and/or premature oxidation of thiol groups on the vector surface. Impurities can be detected by SDS-PAGE and silver staining. In the case that significant impurities occur, vector production should be restarted. In addition, low coupling efficiencies can be caused by free non-vector thiols in the reaction. Therefore, it is advised not to use  $\beta$ -mercaptoethanol or dithiothreitol as reducing reagents, since both contain free thiol groups. Of note, to select solvent-accessible sites to introduce cysteine residues that can readily be modified, crystal structures should be used; otherwise, the cysteines may not be accessible to the coupling partner. Premature oxidation of thiols on the vector surface can be avoided by the stringent use of argon and/or TCEP.

Finally, incorrect stoichiometric calculations can also lead to low coupling efficiencies. The following example is meant to illustrate the generic formula presented above and facilitate the



stoichiometric calculations. In the example, one cysteine is introduced into the hexon capsomere. The titer of vector particles after the first CsCl step gradient purification is determined as  $1.5 \times 10^{10}$  vector particles per  $\mu\text{L}$ , and as coupling moiety, malPEG-750 is used. Each vector capsid contains 720 hexon proteins (240 trimers), so the titer of cysteines per  $\mu\text{L}$  therefore sums to  $720 \times 1.5 \times 10^{10} = 1.08 \times 10^{13}$  cysteines/ $\mu\text{L}$ . In order to modify 1.5 mL of vector particles, a total of  $1.62 \times 10^{16}$  cysteines must be reacted with the coupling moiety. To reach efficient coupling, a 50x molar excess of the coupling compound to the total of cysteine residues is recommended:  $1.62 \times 10^{16} \times 50 = 8.1 \times 10^{17}$  molecules of malPEG-750 is needed to efficiently couple to the  $1.5 \times 10^{16}$  cysteines of 1.5 mL of vector solution purified by the first CsCl step gradient. MalPEG-750 exhibits a molecular weight of 750 Da; hence,  $6.022 \times 10^{23}$  molecules of malPEG-750 weigh 750 g. Therefore, for efficient coupling of the  $1.62 \times 10^{16}$  cysteine residues in 1.5 mL of vector solution with a 50x excess of malPEG-750,  $8.1 \times 10^{17}$  molecules of malPEG-750 =  $(750 \times 8.1 \times 10^{17}) / (6,022 \times 10^{23}) = 1 \times 10^{-3} \text{ g} = 1 \text{ mg}$  malPEG-750 are required.

The presented method complements and exceeds the method of vector PEGylation. Conventional, amine-directed vector PEGylation does not allow for site-specific attachment of shielding or targeting moieties, whereas the geneti-chemical coupling technology presented here can be used to precisely attach moieties to adenovirus vector surfaces at defined positions but and in defined copy numbers. Therefore, it is suitable for both shielding and targeting of adenovirus vector particles.

Of note, this protocol can also be used for a conventional amine-directed PEGylation of Ad vectors mentioned above. In that case, the reducing reagent TCEP can be omitted from the buffers. For stoichiometric calculations, the number of accessible amine groups per particle can be considered to be 18,000, and typical molar excesses of amine-reactive coupling moieties are 20-100 fold.

#### DISCLOSURES:

The authors have nothing to disclose.

#### REFERENCES:

1. Benko, M., Harrach, B. Molecular evolution of adenoviruses. *Current Topics in Microbiology and Immunology*. **272**, 3–35 (2003).
2. Davison, A. J., Benko, M., Harrach, B. Genetic content and evolution of adenoviruses. *Journal of Genetic Virology*. **84**, 2895–2908 (2003).
3. Rowe, W. P., Huebner, R. J., Gilmore, L. K., Parrott, R. H., Ward, T. G. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. *Proceedings of the Society for Experimental Biology and Medicine (New York, N.Y.)*. **84**, 570–573 (1953).
4. van Oostrum, J., Burnett, R. M. Molecular composition of the adenovirus type 2 virion. *Journal of Virology*. **56**, 439–448 (1985).
5. Stewart, P. L., Fuller, S. D., Burnett, R. M. Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. *The EMBO Journal*. **12**, 2589–2599 (1993).


6. Stewart, P. L., Burnett, R. M., Cyrklaff, M., Fuller, S. D. Image reconstruction reveals the complex molecular organization of adenovirus. *Cell*. **67**, 145–154 (1991).
7. Meier, O., *et al.* Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. *Journal of Cellular Biology*. **158**, 1119–1131 (2002).
8. Xu, Z., *et al.* Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. *Nature Medicine*. **19**, 452–457 (2013).
9. Qiu, Q., *et al.* Impact of natural IgM concentration on gene therapy with adenovirus type 5 vectors. *Journal of Virology*. **89**, 3412–3416 (2015).
10. Alemany, R., Suzuki, K., Curiel, D. T. Blood clearance rates of adenovirus type 5 in mice. *Journal of Genetic Virology*. **81**, 2605–2609 (2000).
11. Smith, J. S., Xu, Z., Tian, J., Stevenson, S. C., Byrnes, A. P. Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. *Human Gene Therapy*. **19**, 547–554 (2008).
12. Schiedner, G., *et al.* A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. *Human Gene Therapy*. **14**, 1631–1641 (2003).
13. Xu, Z., Tian, J., Smith, J. S., Byrnes, A. P. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. *Journal of Virology*. **82**, 11705–11713 (2008).
14. Khare, R., Reddy, V. S., Nemerow, G. R., Barry, M. A. Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. *Journal of Virology*. **86**, 2293–2301 (2012).
15. Piccolo, P., Annunziata, P., Mithbaekar, P., Brunetti-Pierri, N. SR-A and SREC-I binding peptides increase HDAd-mediated liver transduction. *Gene Therapy*. **21**, 950–957 (2014).
16. Plüddemann, A., Neyen, C., Gordon, S. Macrophage scavenger receptors and host-derived ligands. *Methods (San Diego, Calif.)*. **43**, 207–217 (2007).
17. Ganesan, L. P., *et al.* Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. *PLoS Pathogen*. **7**, e1002281 (2011).
18. Cichon, G., *et al.* Titer determination of Ad5 in blood: a cautionary note. *Gene Therapy*. **10**, 1012–1017 (2003).
19. Carlisle, R. C., *et al.* Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. *Blood*. **113**, 1909–1918 (2009).
20. Waddington, S. N., *et al.* Adenovirus serotype 5 hexon mediates liver gene transfer. *Cell* **132**, 397–409 (2008).
21. Kalyuzhniy, O., *et al.* Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. *Proceedings of the National Academy of Sciences USA*. **105**, 5483–5488 (2008).
22. Vigant, F., *et al.* Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. *Molecular Therapy: The Journal of the American Society of Gene Therapy*. **16**, 1474–1480 (2008).
23. Jonsson, M. I., *et al.* Coagulation factors IX and X enhance binding and infection of adenovirus types 5 and 31 in human epithelial cells. *Journal of Virology*. **83**, 3816–3825 (2009).
24. Bradshaw, A. C., *et al.* Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. *PLoS Pathogen*. **6**, e1001142 (2010).

25. Duffy, M. R., Bradshaw, A. C., Parker, A. L., McVey, J. H., Baker, A. H. A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes. *Journal of Virology*. **85**, 10914–10919 (2011).
26. Xu, Z., *et al.* Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. *Nature Medicine*. **19**, 452–457 (2013).
27. Prill, J.-M., *et al.* Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. *Molecular Therapy: The Journal of the American Society of Gene Therapy*. **19**, 83–92 (2011).
28. Zaiss, A. K., *et al.* Hepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo. *Journal of Virology*. **90**, 412–420 (2015).
29. Delgado, C., Francis, G. E., Fisher, D. The uses and properties of PEG-linked proteins. *Critical Reviews in Therapeutic Drug Carrier Systems*. **9**, 249–304 (1992).
30. Parveen, S., Sahoo, S. K. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. *Clin. Pharmacokinet*. **45**, 965–988 (2006).
31. O’Riordan, C. R., *et al.* PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. *Human Gene Therapy*. **10**, 1349–1358 (1999).
32. Subr, V., *et al.* Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. *Journal of Controlled Release*. **135**, 152–158 (2009).
33. Kreppel, F., Gackowski, J., Schmidt, E., Kochanek, S. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. *Molecular Therapy: The Journal of the American Society of Gene Therapy*. **12**, 107–117 (2005).
34. Corjon, S., *et al.* Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. *Molecular Therapy: The Journal of the American Society of Gene Therapy*. **16**, 1813–1824 (2008).
35. Prill, J.-M., *et al.* Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. *Molecular Therapy: The Journal of the American Society of Gene Therapy*. **19**, 83–92 (2011).
36. Krutzke, L., *et al.* Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity. *Journal of Controlled Release*. **235**, 379–392 (2016).
37. Prill, J.-M., *et al.* Traceless bioresponsive shielding of adenovirus hexon with HEMA copolymers maintains transduction capacity in vitro and in vivo. *PloS One*. **9**, e82716 (2014).
38. Kratzer, R. F., Kreppel, F. Production, Purification, and Titration of First-Generation Adenovirus Vectors. *Methods in Molecular Biology (Clifton, NJ)*. **1654**, 377–388 (2017).
39. Blum, H., Beier, H., Gross, H. J. Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. *ELECTROPHORESIS*. **8**, 93–99 (1987).



Figure 1

[Click here to access/download;Figure;Fig 1.pdf](#)


specific chemical modification








**A****B****C**







Click here to access/download  
**Video or Animated Figure**  
Fig 2 incl scale bars.svg



Name of Material/ Equipment	Company	Catalog Number
<b>Vector purification and chemical modification</b>		
Argon gas	Air liquide	local gas dealer
Liquid Nitrogen	Air liquide	local gas dealer
500 mL centrifuge tubes	Corning	431123
Stericup Express Plus 0.22 µm	Millipore	SCGPU02RE
Tris(2-carboxyethyl) phosphine (TCEP)	Sigma-Aldrich	C4706-10g
2 mL (3mL) Norm Ject (syringes)	Henke Sass Wolf	4020.000V0
Fine-Ject needles for single use (yellow 0.9 x 40 mm)	Henke Sass Wolf	4710009040
Caesium chloride 99.999% Ultra Quality	Roth	8627.1
Silica gel beads	Applichem	A4569.2500
Methoxypolyethylene glycol maleimide - 750 (PEG mal-750)	Iris Biotech	
13.2 mL Ultra Clear Ultracentrifuge Tubes	Beckman Coulter	344059
PD-10 size exclusion chromatography column	GE Healthcare	17-0851-01
Hepes	AppliChem	A1069.1000
SDS Ultrapure	AppliChem	A1112,0500
Glycerol	AppliChem	A1123.1000
<b>Material for cell-culture</b>		
DPBS	PAN Biotech	P04-36500
DMEM	PAN Biotech	P04-03590
Trypsin/EDTA	PAN Biotech	P10-0231SP
FBS Good	PAN Biotech	P40-37500
Penicillin/Streptomycin	PAN Biotech	P06-07100
Biosphere Filter Tips (various sizes)	Sarstedt	
Serological Pipettes (various sizes)	Sarstedt	
reaction tubes (various sizes)	Sarstedt	
TC plates 15cm	Sarstedt	83.3903
<b>Material for silver staining protocol</b>		
Methanol	J.T.Baker	8045
Ethanol absolute	AppliChem	1613,2500PE



Acetic Acid	AppliChem	A0820,2500PE
Formaldehyde 37%	AppliChem	A0877,0250
Ethanol absolute	AppliChem	A1613,2500PE
Sodium thiosulfate	AppliChem	1,418,791,210
Silver nitrate	AppliChem	A3944.0025
Sodium carbonate	AppliChem	A3900,0500

### **Special Lab Equipment**

Desiccator	Nalgene	5311-0250
Megafuge 40	Heraeus	
Roter for Megafuge TX750 + Adapter and Lids for 500 mL tubes	Heraeus	
Water bath	Conventional	
Ultracentrifuge <i>e.g.</i> Optima XPN-80	Beckman Coulter	
suitable Ultracentrifuge Rotor <i>e.g.</i> SW41	Beckman Coulter	
pH -Meter	Conventional	
Stand with clamps	Conventional	
Goose neck lamp	Conventional	
Over-head rotor	Conventional	
Thermal Block	Conventional	
Photometer (OD 260)	Conventional	

## Comments/Description

store in silica gel beads at -80 °C

only open in hood

store at 4 °C



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

COMBINED GENETIC AND CHEMICAL CAPSID MODIFICATIONS OF ADENOVIRUS...

Author(s):

JOENSSON, F.; HAGEOORN, C.; KREPPLE, P.

Item 1 (check one box): The Author elects to have the Materials be made available (as described at

<http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):



The Author is NOT a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. Background. The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name:

KREPPPEL, FLORIAN

Department:

CHAIR FOR BIOCHEMISTRY AND MOLECULAR MEDICINE

Institution:

UNIVERSITY WITTEN/HERDECKE

Article Title:

COMBINED GENETIC AND CHEMICAL CAPSID MODIFICATIONS OF...

Signature:

*Florian Kreppel*

Date:

May 16, 2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051

August, 14th, 2018

## **Rebuttal document for JoVE58480**

Dear Editor,

We have addressed all editorial comments as suggested. Please find a list of changes below:

1. We proofread the manuscript again.
2. We removed all highlights from notes (lane 330-332; 351-354 and 388-395).
3. We completely highlighted the sentence of lane 440-443.
4. We removed the header from introduction (lane 119).
5. We checked the time units and changed them as required.
6. We rewrote paragraph 3.2.1 in imperative tense.
7. We rewrote paragraph 3.2.13 in imperative tense (lane 381-383) and removed the highlights for filming (lane 381-395).
8. We removed the highlights from paragraph 3.2.14 (lane 397-401).
9. We changed paragraph 4.2.1.1. – 4.2.1.7 to full sentences and imperative tense.
10. We removed all headers from discussion.
11. We changed the troubleshooting list in discussion into continuous text (lane 617-654).
12. We added scale bars to Figure 2.

We hope that everything complies to the journal rules now.

Best regards,

Florian Kreppel